CELL INTELLIGENCE · 肿瘤细胞治疗研究

基于包被溶瘤病毒的“双重打击”策略在胃肠道肿瘤中触发 CD19 CAR-T 治疗

Coated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors.

表达抗 CD47 纳米抗体的溶瘤痘苗病毒通过介导淋巴瘤肿瘤微环境中固有免疫和适应性免疫细胞的浸润与激活发挥增强的抗肿瘤活性

An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration

CAR-T 治疗的困境与下一代创新设计策略

CAR-T therapy dilemma and innovative design strategies for next generation.

缺氧调控的 IL-12 分泌增强 CD19 CAR-T 细胞治疗 DLBCL 的抗肿瘤活性与安全性

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL.

复发/难治性 B-ALL 中与 CAR-T 持久性相关的持久缓解及初代 CAR-T 的长期持久性潜力

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T.

溶瘤单纯疱疹病毒递送 CD19 和 BCMA 双 CAR 靶点及免疫调节剂以增强联合 CAR-T 细胞治疗实体瘤的疗效

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumo

这些研究表明，新一代 oHSV T7011 可与 CD19 或 BCMA 特异性 CAR-T 细胞联合治疗，有望成为治疗多种实体瘤的有前景的联合疗法。

利用 KIRS2/DAP12 结构域的新型双链结构提高复发/难治性 B-ALL 成人患者 CAR-T 细胞的安全性和疗效

Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL.